Response to Letter to the Editor Regarding "Abiraterone Acetate for the Treatment of Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspectiveaof a NICE Single Technology Appraisal"

Bram L. T. Ramaekers; Rob Riemsma; Florian Tomini; Thea van Asselt; Sohan Deshpande; Steven Duffy; Nigel Armstrong; Johan L. Severens; Jos Kleijnen; Manuela A. Joore

doi:10.1007/s40273-017-0507-3

Response to Letter to the Editor Regarding "Abiraterone Acetate for the Treatment of Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspectiveaof a NICE Single Technology Appraisal"

Bram L. T. Ramaekers^*
, Rob Riemsma
, Florian Tomini
, Thea van Asselt
, Sohan Deshpande
, Steven Duffy
, Nigel Armstrong
, Johan L. Severens
, Jos Kleijnen
, Manuela A. Joore

^*Corresponding author for this work

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

73 Downloads (Pure)

Original language	English
Pages (from-to)	665-667
Number of pages	3
Journal	Pharmacoeconomics
Volume	35
Issue number	6
DOIs	https://doi.org/10.1007/s40273-017-0507-3
Publication status	Published - Jun-2017

Access to Document

10.1007/s40273-017-0507-3

Response to Letter to the Editor Regarding “Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate CancerFinal publisher's version, 409 KBLicence: Taverne

Handle.net

Persistent link

Cite this

Ramaekers, B. L. T., Riemsma, R., Tomini, F., van Asselt, T., Deshpande, S., Duffy, S., Armstrong, N., Severens, J. L., Kleijnen, J., & Joore, M. A. (2017). Response to Letter to the Editor Regarding "Abiraterone Acetate for the Treatment of Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspectiveaof a NICE Single Technology Appraisal". Pharmacoeconomics, 35(6), 665-667. https://doi.org/10.1007/s40273-017-0507-3

@article{a740b882dfea483a90049cd6e305e279,

title = "Response to Letter to the Editor Regarding {"}Abiraterone Acetate for the Treatment of Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspectiveaof a NICE Single Technology Appraisal{"}",

author = "Ramaekers, \{Bram L. T.\} and Rob Riemsma and Florian Tomini and \{van Asselt\}, Thea and Sohan Deshpande and Steven Duffy and Nigel Armstrong and Severens, \{Johan L.\} and Jos Kleijnen and Joore, \{Manuela A.\}",

year = "2017",

month = jun,

doi = "10.1007/s40273-017-0507-3",

language = "English",

volume = "35",

pages = "665--667",

journal = "Pharmacoeconomics",

issn = "1170-7690",

publisher = "ADIS INT LTD",

number = "6",

}

Ramaekers, BLT, Riemsma, R, Tomini, F, van Asselt, T, Deshpande, S, Duffy, S, Armstrong, N, Severens, JL, Kleijnen, J & Joore, MA 2017, 'Response to Letter to the Editor Regarding "Abiraterone Acetate for the Treatment of Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspectiveaof a NICE Single Technology Appraisal"', Pharmacoeconomics, vol. 35, no. 6, pp. 665-667. https://doi.org/10.1007/s40273-017-0507-3

Response to Letter to the Editor Regarding "Abiraterone Acetate for the Treatment of Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspectiveaof a NICE Single Technology Appraisal". / Ramaekers, Bram L. T.; Riemsma, Rob; Tomini, Florian et al.
In: Pharmacoeconomics, Vol. 35, No. 6, 06.2017, p. 665-667.

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

TY - JOUR

T1 - Response to Letter to the Editor Regarding "Abiraterone Acetate for the Treatment of Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer

T2 - An Evidence Review Group Perspectiveaof a NICE Single Technology Appraisal"

AU - Ramaekers, Bram L. T.

AU - Riemsma, Rob

AU - Tomini, Florian

AU - van Asselt, Thea

AU - Deshpande, Sohan

AU - Duffy, Steven

AU - Armstrong, Nigel

AU - Severens, Johan L.

AU - Kleijnen, Jos

AU - Joore, Manuela A.

PY - 2017/6

Y1 - 2017/6

U2 - 10.1007/s40273-017-0507-3

DO - 10.1007/s40273-017-0507-3

M3 - Comment/Letter to the editor

C2 - 28391508

SN - 1170-7690

VL - 35

SP - 665

EP - 667

JO - Pharmacoeconomics

JF - Pharmacoeconomics

IS - 6

ER -

Ramaekers BLT, Riemsma R, Tomini F, van Asselt T, Deshpande S, Duffy S et al. Response to Letter to the Editor Regarding "Abiraterone Acetate for the Treatment of Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspectiveaof a NICE Single Technology Appraisal". Pharmacoeconomics. 2017 Jun;35(6):665-667. doi: 10.1007/s40273-017-0507-3